Expert Financial Analysis and Reporting

Recent Reports

• Antares: Multiple New Product Launches Make for Extreme Complexity in Earnings Forecasts for 2019 to 2021 (ATRS, Buy, $3.59) (0)

Recent Blogs

• Brief Updates on Key Buy Recommendations (0)
• Cryoport: Detailed Update and Updated Projections Based on 3Q Results (CYRX, Buy, $10.35) (0)
• Portola: Critical Upcoming Catalysts Have the Potential to Cause a Sharp Upward Move in the Stock (PTLA,  Buy, $29.19) (0)
• Antares: Xyosted is Approved; Let the Good Times Roll (ATRS, Buy, $3.77) (0)
• Update on Currently Recommended Stocks of SmithOnStocks.com (0)
• Regenerative Medicine: Thoughts on How to Invest in This Dynamic New Technology (0)
• Novartis Releases Three Month Interim Data for JULIET Trial of CTL-019 in r/r DLBCL (0)
• Portola: Reiteration of Buy Recommendation (PTLA, Buy, S27.46) (0)
• FDA Announces July 12 AdCom Meeting for CTL-019: Thoughts on How This Might Affect Investor Perceptions of Kite (KITE, Neutral, $80.25) and Cryoport (CYRX, Buy, $3.89) (0)
• Antares: Investment Story has Shifted from Pipeline Promise to Commercial Potential (ATRS, $3.74, Buy) (0)
• Northwest Biotheraputics to Make Presentation at ASCO Today Monday June 5, 2017 (0)

Social Feeds

• • $NWBO Patient demand for DCVax-L under Right to Try law could be overwhelming. Each 100 patients treated could g… https://t.co/w04ue7hSfd, Jun 13
  • $NWBO Five Spectacular Patient Outcomes for Patients Treated with DCVax-L as Reported at ASCO See the report at… https://t.co/MfIpnAJM8W, Jun 05
  • $nwbo After listening to the testimonials on the webcast, I think that this will go viral and many, many GBM patien… https://t.co/HoR7ymIzvf, Jun 04
  • $NWBO Right to Try Law Potentially Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L https://t.co/F1Az4pfVGx, Jun 03
  • $NWBO Temp website hack resolved. See new rprt Blinded Data from Phase 3 Trial Strongly Suggests that DCVax-L is a… https://t.co/upRUAlnwLY, May 30